Fundación GECP
26
7
16
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.8%
1 terminated/withdrawn out of 26 trials
88.9%
+2.4% vs industry average
12%
3 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
Role: lead
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
Role: lead
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
Role: lead
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
Role: lead
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Role: lead
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Role: lead
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
Role: lead
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Role: lead
NADIM II: Neo-Adjuvant Immunotherapy
Role: lead
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
Role: lead
Pathological Response After Neoadjuvant Treatment on NSCLC
Role: lead
Characteristics of Sexual Dysfunction in Patients With Lung Cancer
Role: lead
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
Role: lead
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Role: lead
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Role: lead
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
Role: lead
PALACE: Cemiplimab Trial According to ctDNA Levels
Role: lead
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Role: lead
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Role: lead
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Role: collaborator